Beckley Psytech
Beckley Psytech is a private, independent biopharmaceutical company dedicated to developing rapid-acting psychedelic medicines to improve mental health treatments. Founded in 2019, it leverages over 20 years of scientific research from the Beckley Foundation. The company focuses on innovative psychedelic compounds, including BPL-003 and ELE-101, aiming to deliver effective, scalable, and accessible treatments for conditions like depression and alcohol use disorder. Beckley Psytech collaborates with academic and industry partners, supports patient involvement, and aims to integrate psychedelic medicines into modern medical practice.
Industries
Nr. of Employees
small (1-50)
Beckley Psytech
Patents
Products
Intranasal mebufotenin (5‑MeO‑DMT) benzoate formulation (clinical-stage)
Synthetic intranasal benzoate formulation designed for single‑dose administration with rapid onset and short clinic time; investigated in Phase I, Phase IIa and randomized Phase IIb dose-finding studies for depression and alcohol use disorder.
Intravenous psilocin prodrug formulation (clinical-stage)
Intravenous formulation stabilising the active metabolite of psilocybin to enable more consistent exposure and substantially shorter treatment duration, developed for supervised clinical administration.
New chemical entities (preclinical library)
A library of novel chemical entities in preclinical development intended to expand the portfolio of short‑acting psychedelic-related compounds.
Intranasal mebufotenin (5‑MeO‑DMT) benzoate formulation (clinical-stage)
Synthetic intranasal benzoate formulation designed for single‑dose administration with rapid onset and short clinic time; investigated in Phase I, Phase IIa and randomized Phase IIb dose-finding studies for depression and alcohol use disorder.
Intravenous psilocin prodrug formulation (clinical-stage)
Intravenous formulation stabilising the active metabolite of psilocybin to enable more consistent exposure and substantially shorter treatment duration, developed for supervised clinical administration.
New chemical entities (preclinical library)
A library of novel chemical entities in preclinical development intended to expand the portfolio of short‑acting psychedelic-related compounds.
Services
Design and conduct of early- to mid-phase clinical studies (Phase I–II) including site coordination, safety monitoring and outcome assessment.
Patient council co‑design, peer support funding and participant experience research to inform trial procedures and integration support.
Design and conduct of early- to mid-phase clinical studies (Phase I–II) including site coordination, safety monitoring and outcome assessment.
Patient council co‑design, peer support funding and participant experience research to inform trial procedures and integration support.
Expertise Areas
- Clinical trial management (Phase I–IIb, randomized and open‑label)
- Formulation development for intranasal and intravenous parenteral delivery
- Drug discovery and preclinical NCE development
- Regulatory strategy and IND-level interactions
Key Technologies
- Intranasal drug delivery formulations
- Intravenous prodrug/stabilised metabolite formulations
- Synthetic benzoate formulation chemistry
- Pharmacokinetics / pharmacodynamics studies
News & Updates
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
The study met its primary and all key secondary endpoints, demonstrating rapid, robust, and durable antidepressant effects with a single dose of BPL-003. The 8 mg and 12 mg doses showed significant improvements in MADRS scores, with good tolerability and short clinic time.
Results from Beckley Psytech’s Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) for Alcohol Use Disorder to be presented at CPDD 2025
Clinical and micro-phenomenology data from the Phase IIa study of BPL-003 for AUD will be presented at the 87th Annual Scientific Meeting of the US College on Problems of Drug Dependence in June 2025.
Beckley Psytech to present data from Phase IIa study of BPL-003 at Society of Biological Psychiatry’s Annual Meeting
Data from Part 1 of the Phase IIa study of BPL-003 for Treatment Resistant Depression will be presented at SOBP 2025.
Beckley Psytech Completes Enrolment in Phase IIb study of BPL-003 for Treatment Resistant Depression
The study aims to evaluate the efficacy and safety of a single dose of BPL-003 in TRD patients, with topline data expected in mid-2025.
Positive topline data from Phase IIa study of ELE-101 for Major Depressive Disorder
ELE-101, a synthetic IV formulation of psilocin benzoate, showed rapid, robust, and lasting antidepressant effects in a small study, with good tolerability and short clinic time.
Beckley Psytech to attend and present at 8th Annual LSX World Congress 2022
Beckley Psytech will introduce its target indications, pipeline, and ongoing trials at the event in May 2022.
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
The study met its primary and all key secondary endpoints, demonstrating rapid, robust, and durable antidepressant effects with a single dose of BPL-003. The 8 mg and 12 mg doses showed significant improvements in MADRS scores, with good tolerability and short clinic time.
Results from Beckley Psytech’s Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) for Alcohol Use Disorder to be presented at CPDD 2025
Clinical and micro-phenomenology data from the Phase IIa study of BPL-003 for AUD will be presented at the 87th Annual Scientific Meeting of the US College on Problems of Drug Dependence in June 2025.
Beckley Psytech to present data from Phase IIa study of BPL-003 at Society of Biological Psychiatry’s Annual Meeting
Data from Part 1 of the Phase IIa study of BPL-003 for Treatment Resistant Depression will be presented at SOBP 2025.
Beckley Psytech Completes Enrolment in Phase IIb study of BPL-003 for Treatment Resistant Depression
The study aims to evaluate the efficacy and safety of a single dose of BPL-003 in TRD patients, with topline data expected in mid-2025.
Positive topline data from Phase IIa study of ELE-101 for Major Depressive Disorder
ELE-101, a synthetic IV formulation of psilocin benzoate, showed rapid, robust, and lasting antidepressant effects in a small study, with good tolerability and short clinic time.
Beckley Psytech to attend and present at 8th Annual LSX World Congress 2022
Beckley Psytech will introduce its target indications, pipeline, and ongoing trials at the event in May 2022.